The effectiveness of immunotherapy relies heavily on the ability of the immune system to recognize and attack cancer cells based on their antigenic profile. Antigen loss can significantly impact the success of therapies such as checkpoint inhibitors and CAR-T cells. When cancer cells lose the antigens targeted by these therapies, they may become resistant, leading to treatment failure. Consequently, understanding and addressing antigen loss is crucial for improving the outcomes of immunotherapy.
